. Author manuscript; available in PMC: 2015 Nov 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2014 Aug 19;23(11):2568–2578. doi: 10.1158/1055-9965.EPI-14-0129

Table 3.

Meta-analysis of the significant associations (p<0.05) between risk variants for cancer and incident multiple primary cancer risk

SNP	First GWAS citation	First GWAS site	Region	Position	Mapped gene	Ca	Co	risk allele/ ref allele	RAF^c	metaOR^a	(95% CI)	P- value	WHI	MEC	p-het for study

													Direction^b
rs578776	Saccone, et al. 2009	nicotine dependence	15q25.1	76,675,455	CHRNA3	1377	9559	C/T	0.49	1.15	(1.05–1.26)	0.004	+	+	0.26
rs11249433	Thomas, et al. 2009	breast cancer	1p11.2	120,982,136	EMBP1	1347	9406	C/T	0.26	1.16	(1.04–1.28)	0.005	+	+	0.59
rs3803662	Thomas, et al. 2009	breast cancer	16q12.1	51,143,842	TOX3	1377	9577	T/C	0.40	1.13	(1.03–1.23)	0.006	+	+	0.50
rs4975616	Broderick, et al. 2009	lung cancer	5p15.33	1,368,660	Intergenic	1378	9576	A/G	0.61	0.89	(0.82–0.98)	0.014	−	−	0.55
rs8042374	Wang, et al. 2008	lung cancer	15q25.1	76,695,087	CHRNA3	1368	9550	A/G	0.57	1.12	(1.02–1.24)	0.015	+	+	0.28
rs4857841	Gudmundsson, et al. 2009	prostate cancer	3q21.3	129,529,333	EEFSEC	1376	9534	A/G	0.44	0.90	(0.82–0.98)	0.020	−	−	0.34
rs4785763	Bishop, et al. 2009	melanoma	16q24.3	88,594,437	AFG3L1P	1370	9551	A/C	0.28	1.11	(1.01–1.22)	0.023	+	+	0.62
rs965513	Gudmundsson, et al. 2009	thyroid cancer	9q22.33	99,595,930	Intergenic	1377	9562	A/G	0.24	0.89	(0.80–0.99)	0.026	−	−	0.42
rs5945619	Eeles, et al. 2008	prostate cancer	Xp11.22	51,258,412	Intergenic	1378	9566	C/T	0.27	1.09	(1.01–1.18)	0.035	+	+	0.73
rs3790844	Petersen, et al. 2010	pancreatic cancer	1q32.1	198,274,055	NR5A2	420	2657	T/C	0.77	1.23	(1.01–1.49)	0.035	+	x	1
rs10086908	Al Olama, et al. 2009	prostate cancer	8q24.21	128,081,119	Intergenic	957	6904	T/C	0.74	1.13	(1.01–1.27)	0.040	x	+	1
rs4939827	Tenesa, et al. 2008	colorectal cancer	18q21.1	44,707,461	SMAD7	1374	9532	T/C	0.39	1.09	(1.00–1.19)	0.047	+	+	0.18

Models were adjusted for age at diagnosis for the index cancer (continuous), sex (MEC only), study design (WHI only: CT vs OS), the most significant principal components

+=positive association, − =negative association, x=not tested

RAF=risk allele frequency